Understanding C-Met Mutated Non-Small Cell Lung Cancer
C-Met (also known as MET) is a gene that encodes the hepatocyte growth factor receptor (HGFR), a protein that regulates cell growth, survival, migration, and invasion. Mutations in the c-Met gene can lead to abnormal activation of signaling pathways, contributing to cancer development and progression. In non-small cell lung cancer (NSCLC), c-Met mutations are relatively rare but significant, occurring in approximately 2–4% of cases.
Epidemiological Insights
The epidemiology of c-Met mutated NSCLC is characterized by the following:
-
Incidence: In 2017, there were 16,658 incident cases of c-Met mutated NSCLC across the seven major markets (7MM: United States, EU5, and Japan).
-
Regional Distribution: The United States accounted for the highest number of cases, approximately 7,202, followed by Germany (2,138), France (1,508), Italy (1,277), the United Kingdom (1,664), and Japan (2,000).
-
Histological Subtypes: Adenocarcinoma is the most common histological subtype, comprising about 47% of cases, followed by squamous cell carcinoma and large cell carcinoma.
Market Landscape and Growth Projections
The market for c-Met mutated NSCLC therapies is poised for growth, driven by advancements in targeted treatments and increasing awareness:
-
Market Size: In 2017, the therapeutic market for NSCLC mutations, including c-Met, was estimated at USD 9,730 million across the 7MM, with projections indicating growth during the study period (2017–2030).
-
Key Players: Leading pharmaceutical companies involved in the development of therapies for c-Met mutated NSCLC include AstraZeneca, BMS, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda, Eli Lilly, Immutep, Sanofi, and GlaxoSmithKline.
-
Innovative Therapies: Several c-Met inhibitors are in development or have been approved, such as:
-
Capmatinib (Tabrecta): Approved for MET exon 14 skipping mutations in NSCLC.
-
Tepotinib (Tepmetko): Approved in Japan and the U.S. for similar indications.
-
Vebreltinib (Bozitinib): Approved in China for MET exon 14+ NSCLC.
-
Onartuzumab (RG3638): Under clinical investigation by Roche.
-
Tivantinib (ARQ 197): Under clinical investigation by Merck & Co.
-
Conclusion
C-Met mutated NSCLC represents a critical area of focus in oncology, with significant implications for patient prognosis and treatment strategies. The evolving landscape of targeted therapies offers hope for improved outcomes, underscoring the importance of continued research and development in this domain.
Click here and download our sample pages @ https://www.delveinsight.com/report-store/cellular-mesenchymal-epithelial-transition-factor-mutated-non-small-cell-lung-cancer-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr
